ABL Bio has secured a significant R&D funding package totaling $55 million from Eli Lilly and Company. This includes a $40 million upfront payment for a license and collaboration agreement concerning ABL Bio's Grabody platform, and a $15 million equity investment. The funds will accelerate ABL Bio's research and development of its bispecific antibody technologies, including expanding the Grabody platform's applications to areas like obesity and muscle disorders, and advancing immuno-oncology candidates.